Sage Therapeutics (NASDAQ:SAGE) Given Hold Rating at Needham & Company LLC

Sage Therapeutics (NASDAQ:SAGE)‘s stock had its “hold” rating reissued by equities research analysts at Needham & Company LLC in a research report issued to clients and investors on Thursday, Benzinga reports.

A number of other research firms have also recently commented on SAGE. Royal Bank of Canada increased their target price on shares of Sage Therapeutics from $21.00 to $26.00 and gave the company a “sector perform” rating in a research report on Thursday, February 15th. Bank of America cut shares of Sage Therapeutics from a “neutral” rating to an “underperform” rating and decreased their target price for the company from $24.00 to $14.00 in a research report on Wednesday. StockNews.com raised shares of Sage Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, February 15th. TD Cowen decreased their price target on shares of Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating for the company in a report on Thursday. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $28.00 price target on shares of Sage Therapeutics in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Sage Therapeutics has an average rating of “Hold” and a consensus price target of $39.89.

Sage Therapeutics Stock Performance

NASDAQ SAGE opened at $12.57 on Thursday. The firm’s 50 day moving average price is $20.06 and its 200-day moving average price is $20.96. Sage Therapeutics has a 52-week low of $10.92 and a 52-week high of $59.99. The company has a market cap of $755.58 million, a PE ratio of -1.39 and a beta of 0.86.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.28) by $0.73. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. The firm had revenue of $77.97 million for the quarter, compared to the consensus estimate of $60.15 million. During the same period last year, the firm earned ($2.47) earnings per share. The company’s quarterly revenue was up 2621.5% on a year-over-year basis. On average, analysts forecast that Sage Therapeutics will post -6.06 earnings per share for the current fiscal year.

Institutional Trading of Sage Therapeutics

Several institutional investors have recently modified their holdings of SAGE. MetLife Investment Management LLC purchased a new position in shares of Sage Therapeutics in the first quarter worth about $34,000. CWM LLC lifted its stake in shares of Sage Therapeutics by 274.2% in the third quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 883 shares in the last quarter. KBC Group NV purchased a new position in shares of Sage Therapeutics in the fourth quarter worth about $28,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Sage Therapeutics by 95.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 748 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Sage Therapeutics in the first quarter worth about $209,000. Institutional investors and hedge funds own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.